Cited 42 times in

Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin

Title
 Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin
Authors
 Pyung-Hwan Kim; Joo-Hyuk Sohn; Chae-Ok Yun; Seungjoo Haam; Sung Wan Kim; Yukyung Jung; Joung-Woo Choi
Issue Date
2011
Journal Title
 Biomaterials
ISSN
 0142-9612
Citation
 Biomaterials, Vol.32(9) : 2314~2326, 2011
Abstract
PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases the accessibility of virus particles to target cells. We tested whether PEGylated Ad conjugated to Herceptin (Ad-PEG-HER) can be used to treat Her2/neu-positive cells in vitro and in vivo to demonstrate the therapeutic feasibility of this Ad formulation. Ad-PEG-HER transduced Her2/neu-overexpressing cancer cells through a specific interaction between Herceptin and Her2/neu. Ad-PEG-HER treatment resulted in higher plasma retention and lower neutralizing antibody and IL-6 production than naked Ad. This formulation was extended to generate a Her2/neu-targeted, PEGylated oncolytic Ad (DWP418-PEG-HER). DWP418-PEG-HER specifically killed Her2/neu-positive cells and performed better than non-targeted and naked Ad in vivo. DWP418-PEG-HER showed a 10(10)-fold increase in the liver to tumor biodistribution compared with naked Ad. Immunohistochemical staining confirmed accumulation of Ad E1A in tumors. These data suggest that targeted gene therapy with the PEGylated Ad conjugated with Herceptin might shed a light on its therapeutic application for metastatic cancer in the future.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/94349
DOI
10.1016/j.biomaterials.2010.10.031
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Medical Research Center
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://www.sciencedirect.com/science/article/pii/S0142961210013384
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse